In fact, although TKIs maintain their efficacy against the BCR-ABL tyrosine kinase, CML stem cells could escape from their oncogenic addiction [11, 12]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.